CEFOTAXIME CTL 32 US S30
Report
- Report Number
- 3002769706-2015-00087
- Event Type
- Malfunction
- Date Received
- September 17, 2015
- Report Date
- July 21, 2015
- Manufacturer
- BIOMERIEUX SA
- Product Code
- JWY
- PMA / PMN Number
- K981137
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- MD, US
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
DEVICE NOT RETURNED TO MANUFACTURER.
THIS REPORT WAS INITIALLY SUBMITTED FOLLOWING NOTIFICATION THAT A CUSTOMER IN THE UNITED STATES REPORTED PSEUDOMONAS AERUGINOSA ATCC® 27853 TM OUT-OF-RANGE-HIGH (MIC >=32) IN ASSOCIATION WITH ETEST® CEFOTAXIME CTL 32. INTERNAL INVESTIGATION WAS CONDUCTED. ETEST® CEFOTAXIME CTL 32 IS ONLY RECOMMENDED FOR STREPTOCOCCUS AND FASTIDIOUS STRAINS. ETEST® CEFOTAXIME CTL 32 IS NOT ADAPTED FOR PSEUDOMONAS AERUGINOSA. THIS IS WHY PSEUDOMONAS AERUGINOSA ATCC® 27853 TM IS NOT RECOMMENDED FOR QUALITY CONTROL TESTING AGAINST THIS PRODUCT. INSTRUCTIONS FOR USE SUPPLEMENTARY INSERT US 15221 STATES TO "PLEASE CONSULT THE FOOTNOTES IN THE LATEST CLSI TABLES FOR FURTHER COMMENTS AND CLARIFICATION. INTERPRETIVE CRITERIA MAY BE DIFFERENT." IN CLSI, THERE ARE NO BREAK POINTS FOR PSEUDOMONAS AERUGINOSA. THE ETEST® CEFOTAXIME CTL 32 PRODUCT IS PERFORMING IN ACCORDANCE TO PERFORMANCE CLAIMS.
A CUSTOMER CALLED WITH OUT OF RANGE RESULTS FOR QC TESTING USING ETEST CEFOTAXIME CTL 32 US S30, (B)(4), LOT 1004047910. QUALITY CONTROL TESTING FOR PSEUDOMONAS AERUGINOSA 27853 WERE OUT OF RANGE (HIGH) AND E. COLI 25922 WAS ACCEPTABLE. ADDITIONAL SET-UP AND TESTING PERFORMED WITH THE SAME RESULTS. PRODUCT FROM A DIFFERENT LOT ARE BEING SENT TO THE CUSTOMER FOR USE. AN INTERNAL INVESTIGATION HAS BEEN LAUNCHED. THERE WAS NO REPORTED DEATH OR SERIOUS INJURY ASSOCIATED WITH THE REFERENCED EVENT.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 614739 | CEFOTAXIME CTL 32 US S30 | CEFOTAXIME CTL 32 US S30 | JWY | BIOMERIEUX SA | 1004047910 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |